A detailed history of Tb Alternative Assets Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Tb Alternative Assets Ltd. holds 487 shares of BGNE stock, worth $110,407. This represents 0.02% of its overall portfolio holdings.

Number of Shares
487
Holding current value
$110,407
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 16, 2026

BUY
N/A
487 New
487 $110,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Tb Alternative Assets Ltd. Portfolio

Follow Tb Alternative Assets Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tb Alternative Assets Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Tb Alternative Assets Ltd. with notifications on news.